Idorsia Ltd (SWX:IDIA)
3.620
+0.090 (2.55%)
Mar 9, 2026, 5:31 PM CET
Idorsia Revenue
In the year 2025, Idorsia had annual revenue of 220.58M CHF with 96.06% growth. Idorsia had revenue of 47.97M in the quarter ending December 31, 2025, a decrease of -19.91%.
Revenue
220.58M
Revenue Growth
+96.06%
P/S Ratio
4.02
Revenue / Employee
339.36K
Employees
650
Market Cap
887.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 232.38M |
| Newron Pharmaceuticals | 55.93M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| BioVersys AG | 1.31M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 839.38K |
| Addex Therapeutics | 158.54K |
Idorsia News
- 5 days ago - Idorsia Ltd (IDRSF) Full Year 2025 Earnings Call Highlights: Strong Quvivic Sales and Strategic ... - GuruFocus
- 5 days ago - Full Year 2025 Idorsia Ltd Earnings Call Transcript - GuruFocus
- 11 days ago - Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 - GlobeNewsWire
- 25 days ago - Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call - GlobeNewsWire
- 5 weeks ago - Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium - GlobeNewsWire
- 5 weeks ago - Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America - GlobeNewsWire
- 2 months ago - Idorsia to present at J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 2 months ago - Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease - GlobeNewsWire